Berry Smith Supports Axol Bioscience in Fight Against Alzheimer’s.

Axol Bioscience and StrataStem have teamed up in the fight against Alzheimer’s Disease. Axol Bioscience are a stem cell technology provider specialising in induced pluripotent stem cell (iPSC) technology for disease research and drug discovery. Among several capabilities (including gene editing, cell reprogramming and other custom lab services), Axol have developed an extensive cell line library that can be licensed to third parties for research into various types of neurodegenerative diseases.

Supported by Senior Associate at Berry Smith, Dan Dowen, the exclusive deal between the two UK-based businesses will see Axol Bioscience reprogram cell samples from Alzheimer’s patients obtained by StrataStem, into “iPSC lines” that can be used for further research and study into Alzheimer’s Disease.

The in vitro strategy used by Axol provides an effective substitute for current in vivo techniques and has the potential to speed up drug discovery and development for Alzheimer’s Disease while lowering risk and cost.

Dan commented “I am delighted to have been involved in this deal between Axol and StrataStem;Axol and Liam were a pleasure to work with. The work carried out between Axol and StrataStem is obviously for a fantastic cause and will no doubt lead to further understanding of such a severe and devastating disease.”

Liam Taylor, CEO of Axol Bioscience said “this exclusive agreement with StrataStem brings us to the forefront of Alzheimer’s Disease drug discovery and development, and we are proud to be among the first to actively source panels of patient samples with comprehensive longitudinal data to do this. We’d like to thank Dan Dowen and Berry Smith for their assistance and encouragement in getting this exciting agreement over the line.”

If you would like to find out more about Berry Smith LLP and think we could assist you and your business, then please contact us.

Dan Dowen – Senior Associate – Commercial & IP